Table 6.
Quiescent vs most severe | Quiescent vs all other patients | Most severe vs all other patients | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sens | Spec | AUROC | p-value | Sens | Spec | AUROC | p-value | Sens | Spec | AUROC | p-value | |
Montreal classificationa | 0.678 | 0.638 | 0.715 | <0.001 | 0.678 | 0.594 | 0.697 | <0.001 | 0.610 | 0.656 | 0.683 | <0.001 |
All baseline variablesb | 0.617 | 0.766 | 0.770 | <0.001 | 0.593 | 0.722 | 0.722 | <0.001 | 0.553 | 0.710 | 0.687 | <0.001 |
Baseline variables and 6 month follow-up combinedc | 0.677 | 0.755 | 0.793 | <0.001 | 0.634 | 0.754 | 0.779 | <0.001 | 0.589 | 0.679 | 0.701 | <0.001 |
PLS, partial least square; Sens, sensitivity; Spec, specificity; AUROC, area under the receiver operating characteristic curve.
aAge, disease localisation, disease behaviour, perianal disease, upper gastrointestinal involvement.
bMontreal classification and gender, smoking status, and surgery at diagnosis.
cAll baseline variables and disease progression, need for resective surgery, need for prednisone, need for immunomodulators, need for biologics, and need for hospitalisation within the first 6 months after diagnosis.